放射性核素在帕金森病诊断中的应用

doi:10.16150/j.1671-2870.2018.06.020

摘要/Abstract

关键词: 帕金森病, α-突触核蛋白, 多巴胺, 正电子发射断层显像, 单光子发射断层显像, Tau蛋白

中图分类号:

R742

武冬冬, 刘银红, 蒋景文, 陈海波. 放射性核素在帕金森病诊断中的应用[J]. 诊断学理论与实践, 2018, 17(06): 726-730.

[1] Lin SC, Lin KJ, Hsiao IT, et al.In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET[J]. J Nucl Med,2014,55(1):73-79.
[2] Perlmutter JS, Norris SA.Neuroimaging biomarkers for Parkinson disease: facts and fantasy[J]. Ann Neurol,2014, 76(6):769-783.
[3] Lee CS, Samii A, Sossi V, et al.In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease[J]. Ann Neurol,2000,47(4):493-503.
[4] Ginovart N, Galineau L, Willeit M, et al.Binding characteristics and sensitivity to endogenous dopamine of [¹¹C]-(+)-PHNO, a new agonist radiotracer for imaging the high-affinity state of D2 receptors in vivo using positron emission tomography[J]. J Neurochem,2006,97(4):1089-1103.
[5] Nandhagopal R, Kuramoto L, Schulzer M, et al.Longitudinal evolution of compensatory changes in striatal dopamine processing in Parkinson's disease[J]. Brain,2011,134(Pt 11):3290-3298.
[6] Remy P, Doder M, Lees A, et al.Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system[J]. Brain,2005,128(Pt 6):1314-1322.
[7] Politis M, Wu K, Loane C, et al.Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study[J]. Neurobiol Dis,2010,40(1):216-221.
[8] Bohnen NI, Kaufer DI, Ivanco LS, et al.Cortical choli-nergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study[J]. Arch Neurol,2003,60(12):1745-1748.
[9] Bohnen NI, Müller ML, Koeppe RA, et al.History of falls in Parkinson disease is associated with reduced cholinergic activity[J]. Neurology,2009,73(20):1670-1676.
[10] Gjerløff T, Fedorova T, Knudsen K, et al.Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with ¹¹C-donepezil PET[J]. Brain,2015,138(Pt 3):653-663.
[11] Niethammer M, Eidelberg D.Metabolic brain networks in translational neurology: concepts and applications[J]. Ann Neurol,2012,72(5):635-647.
[12] Shah M, Seibyl J, Cartier A, et al.Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers[J]. J Nucl Med,2014,55(9):1397-1400.
[13] Bagchi DP, Yu L, Perlmutter JS, et al.Binding of the radioligand SIL23 to α-synuclein fibrils in Parkinson di-sease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent[J]. PLoS One,2013,8(2):e55031.
[14] Petrou M, Dwamena BA, Foerster BR, et al.Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review[J]. Mov Disord,2015,30(7):928-935.
[15] Villemagne VL, Fodero-Tavoletti MT, Masters CL, et al.Tau imaging: early progress and future directions[J]. Lancet Neurol,2015,14(1):114-124.
[16] Compta Y, Parkkinen L, Kempster P, et al.The significance of α-synuclein, amyloid-β and tau pathologies in Parkinson's disease progression and related dementia[J]. Neurodegener Dis,2014,13(2-3):154-156.
[17] Hirsch EC, Hunot S.Neuroinflammation in Parkinson's disease: a target for neuroprotection?[J]. Lancet Neurol,2009,8(4):382-397.
[18] Ouchi Y, Yoshikawa E, Sekine Y, et al.Microglial activation and dopamine terminal loss in early Parkinson's disease[J]. Ann Neurol,2005,57(2):168-175.
[19] Gerhard A, Pavese N, Hotton G, et al.In vivo imaging of microglial activation with [¹¹C](R)-PK11195 PET in idiopathic Parkinson's disease[J]. Neurobiol Dis,2006,21(2):404-412.
[20] Adams JR, van Netten H, Schulzer M, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's di-sease and evidence for presymptomatic compensation[J]. Brain,2005,128(Pt 12):2777-2785.
[21] Stoessl AJ.Positron emission tomography in premotor Parkinson's disease[J]. Parkinsonism Relat Disord,2007, 13(Suppl 3):S421-S424.
[22] Sakakibara R, Tateno F, Kishi M, et al.MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review[J]. Parkinsonism Relat Disord,2014,20(3):267-273.
[23] Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study[J]. Brain.2009 Nov,132(Pt 11):2970-2979.
[24] de la Fuente-Fernández R, Schulzer M, Kuramoto L, et al. Age-specific progression of nigrostriatal dysfunction in Parkinson's disease[J]. Ann Neurol,2011,69(5):803-810.
[25] Stoessl AJ.Central pharmacokinetics of levodopa: Lessons from imaging studies[J]. Mov Disord,2015,30(1):73-79.
[26] Politis M, Wu K, Loane C, et al.Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients[J]. J Clin Invest,2014,124(3):1340-1349.
[27] Ahmed I, Bose SK, Pavese N, et al.Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias[J]. Brain,2011,134(Pt 4):979-986.
[28] Ramlackhansingh AF, Bose SK, Ahmed I, et al.Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease[J]. Neurology,2011, 76(21):1811-1816.

放射性核素在帕金森病诊断中的应用

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	武冬冬, 陈玉辉, 刘芳, 刘银红, 蒋景文. 脑小血管疾病合并中枢神经系统退行性疾病机制的研究进展[J]. 诊断学理论与实践, 2022, 21(05): 644-649.
[2]	屈骞, 海汪溪, 胡生焰, 张敏, 陈肖玥, 周熠磊, 王瑾, 胡晓平, 李彪, 胡佳佳. 多巴胺转运蛋白显像探针¹⁸F-FP-CIT的AllinOne模块自动化制备及大鼠基底节Micro PET/CT显像[J]. 诊断学理论与实践, 2022, 21(04): 482-489.
[3]	陈施吾, 窦荣花, 王玉凯, 王含, 王晓平, 陈先文, 陈玲, 王训, 屈洪党, 陈生弟, Susan Fox, 李燕, 王刚. 帕金森病血压管理专家共识[J]. 诊断学理论与实践, 2020, 19(05): 460-468.
[4]	邵丹丹, 付洋, 罗琪, 陈捷, 马建芳, 黄雷. 血清尿酸水平与帕金森病发病间关系的前瞻性研究[J]. 诊断学理论与实践, 2020, 19(02): 139-144.
[5]	严振鹏, 杨月嫦, 吴惠涓, 陈坤, 徐云霞. 1例多方案评估帕金森病睡眠障碍治疗疗效的病例报告[J]. 诊断学理论与实践, 2018, 17(04): 457-459.
[6]	邹扬, 崔海伦, 胡勇博, 高颖, 张月琪, 陈生弟, 王刚. 运动诱发电位用于鉴别诊断原发性帕金森病和多系统萎缩的临床研究[J]. 诊断学理论与实践, 2018, 17(04): 409-413.
[7]	刘春风, 徐兴, 沈赟. 多导睡眠监测在帕金森病伴发睡眠障碍诊断中的应用[J]. 诊断学理论与实践, 2018, 17(04): 377-381.
[8]	曹学兵, 曾玮琪, 徐岩. 帕金森病冻结步态诊疗研究进展[J]. 诊断学理论与实践, 2018, 17(04): 382-386.
[9]	崔海伦, 张一帆, 管晓军, 黄沛钰, 刘志蓉, 袁园, 刘晓云, 朱红灿, 曹学兵, 陈玲, 陈先文, 陈燕, 商慧芳, 杨任民, 陈生弟, 张敏鸣, 王刚. 帕金森病及相关运动障碍的神经影像学诊断专家共识[J]. 诊断学理论与实践, 2018, 17(04): 403-408.
[10]	崔诗爽, 陈生弟, 王刚. 帕金森病体液生物标志物研究进展[J]. 诊断学理论与实践, 2018, 17(04): 471-476.
[11]	贺娜英, 许洪敏, 黄沛, 陈生弟, 严福华, 凌华威. 基于定量磁化率图像观察帕金森病患者黑质体-1退变的研究[J]. 诊断学理论与实践, 2017, 16(02): 147-151.
[12]	沈博, 尤志菲, 王晓平,. 丘脑底核脑深部电刺激对帕金森病认知功能影响[J]. 诊断学理论与实践, 2016, 15(02): 128-132.
[13]	张巍,. 经颅黑质超声与帕金森病的诊断及评估[J]. 诊断学理论与实践, 2016, 15(02): 108-112.
[14]	商慧芳, 陈永平,. 帕金森病生物标志物的研究现状及展望[J]. 诊断学理论与实践, 2016, 15(02): 92-95.
[15]	王坚, 刘振洋,. 帕金森病的PET/SPECT分子成像研究认识[J]. 诊断学理论与实践, 2016, 15(02): 102-107.